Daré Bioscience Q2 FY26 net loss narrows to $2.98 million; revenue rises to $187,546

Flora Sync LF5 began generating revenue in July; DARE to PLAY Sildenafil Cream dispensing and initial revenue are expected to start in Q3 2026.

Daré Bioscience posted a Q2 net loss of $2.98 million, narrowing from $4.02 million a year earlier; loss per share improved to $0.20.

Revenue rose to $187,546 from negative $21,172, reflecting Gates Foundation R&D services, partly offset by lower non-cash XACIATO royalty revenue.

Operating loss narrowed to $2.97 million from $3.83 million, while R&D expense fell to $241,966 from $1.43 million on higher contra-R&D offsets.

Cash and cash equivalents totaled $12.62 million at June 30, 2026, down from $24.71 million at Dec. 31, 2025.